BACKGROUND: Endometrial cancer (EC) is the most common cancer of the female genital tract. However, no screening method for EC has been established yet. In this study, we evaluated the cell-free DNA in EC. METHODS: Fifteen healthy individuals, 9 with benign gynecologic diseases, and 53 with ECs were included in this study. Alu sequences in free DNA fragments were used as surrogate markers, and cell-free DNA density was measured by quantitative real-time polymerase chain reaction. RESULTS: The cell-free DNA levels in ECs tended to be higher than in benign condition (healthy individuals + benign gynecologic diseases, n = 24; P = 0.095). There was no significant difference in cell-free DNA among stage or histological grade of EC, and no significant change in cell-free DNA before and after operation (P = 0.25): Moreover, in 19 ECs, cell-free DNA decreased after operation, however, in 6 ECs, cell-free DNA did not decrease. Three ECs recurred, and cell-free DNA did not decrease in these cases. CONCLUSIONS: Measurement of cell-free DNA is not useful for EC screening; however, the change of cell-free DNA in a patient may be a prognostic biomarker of EC.
BACKGROUND:Endometrial cancer (EC) is the most common cancer of the female genital tract. However, no screening method for EC has been established yet. In this study, we evaluated the cell-free DNA in EC. METHODS: Fifteen healthy individuals, 9 with benign gynecologic diseases, and 53 with ECs were included in this study. Alu sequences in free DNA fragments were used as surrogate markers, and cell-free DNA density was measured by quantitative real-time polymerase chain reaction. RESULTS: The cell-free DNA levels in ECs tended to be higher than in benign condition (healthy individuals + benign gynecologic diseases, n = 24; P = 0.095). There was no significant difference in cell-free DNA among stage or histological grade of EC, and no significant change in cell-free DNA before and after operation (P = 0.25): Moreover, in 19 ECs, cell-free DNA decreased after operation, however, in 6 ECs, cell-free DNA did not decrease. Three ECs recurred, and cell-free DNA did not decrease in these cases. CONCLUSIONS: Measurement of cell-free DNA is not useful for EC screening; however, the change of cell-free DNA in a patient may be a prognostic biomarker of EC.
Authors: Tommaso Grassi; Faye R Harris; James B Smadbeck; Stephen J Murphy; Matthew S Block; Francesco Multinu; Janet L Schaefer Klein; Piyan Zhang; Giannoula Karagouga; Minetta C Liu; Alyssa Larish; Maureen A Lemens; Marla Kay S Sommerfield; Serena Cappuccio; John C Cheville; George Vasmatzis; Andrea Mariani Journal: PLoS One Date: 2021-06-10 Impact factor: 3.240
Authors: Carlos Casas-Arozamena; Eva Díaz; Cristian Pablo Moiola; Lorena Alonso-Alconada; Alba Ferreirós; Alicia Abalo; Carlos López Gil; Sara S Oltra; Javier de Santiago; Silvia Cabrera; Victoria Sampayo; Marta Bouso; Efigenia Arias; Juan Cueva; Eva Colas; Ana Vilar; Antonio Gil-Moreno; Miguel Abal; Gema Moreno-Bueno; Laura Muinelo-Romay Journal: J Clin Med Date: 2020-02-21 Impact factor: 4.241
Authors: Gregory M Gressel; Elaine C Maggi; Bryan E Harmon; Kenny Q Ye; D Y S Kuo; Siobhan M Dolan; Cristina Montagna Journal: J Transl Med Date: 2020-08-27 Impact factor: 5.531